Selecta Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

On August 2, 2021, Selecta Biosciences, a biotechnology company focused on immunotherapies, announced CEO Carsten Brunn's participation in two upcoming investor conferences. The conferences are the BTIG Virtual Biotechnology Conference on August 9, 2021, at 3:00 p.m. EDT, and the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 9:30 a.m. EDT. Selecta Biosciences leverages its ImmTOR™ platform to develop therapies that mitigate unwanted immune responses, with several proprietary and partnered programs in its pipeline.

WATERTOWN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in upcoming investor conferences in August.

Details on the panel can be found below.

• BTIG Virtual Biotechnology Conference 2021
  Format: Fireside chat and one-on-one investor meetings
  Date: Monday, August 9, 2021
  Presentation Time: 3:00 p.m. EDT

• Canaccord Genuity 41^st Annual Growth Conference
  Format: Fireside chat and one-on-one investor meetings
  Date: Wednesday, August 11, 2021
  Presentation Time: 9:30 a.m. EDT
  Webcast: Click Here

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative. An archived webcast of the Canaccord corporate update will be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com 

FAQ

What are the dates for the investor conferences involving SELB?

Selecta Biosciences will participate in the BTIG Virtual Biotechnology Conference on August 9, 2021, and the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021.

What time is the presentation for the BTIG Virtual Biotechnology Conference for SELB?

The presentation at the BTIG Virtual Biotechnology Conference is scheduled for 3:00 p.m. EDT on August 9, 2021.

Where can I watch the Canaccord Genuity 41st Annual Growth Conference for SELB?

You can watch the Canaccord Genuity 41st Annual Growth Conference for Selecta Biosciences via a webcast available on their website.

What is the focus of Selecta Biosciences as stated in the press release?

Selecta Biosciences focuses on leveraging its ImmTOR™ platform to develop tolerogenic therapies that reduce unwanted immune responses.